Cdk3 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol acts as a selective inhibitor of Cdk3, showcasing a unique binding affinity that disrupts the enzyme's active site. Its interaction is characterized by a combination of hydrogen bonding and hydrophobic contacts, which stabilize the inhibitor-enzyme complex. This modulation of Cdk3 activity alters downstream signaling pathways, affecting cell cycle progression. The compound's kinetic profile reveals a competitive inhibition mechanism, influencing substrate turnover and cellular dynamics. | ||||||
10Z-Hymenialdisine | 82005-12-7 | sc-360987 | 500 µg | $210.00 | ||
10Z-Hymenialdisine exhibits a distinctive mechanism of action as a Cdk3 inhibitor, characterized by its ability to form specific non-covalent interactions with the enzyme's regulatory domains. This compound alters the conformational dynamics of Cdk3, leading to a reduction in kinase activity. Its unique structural features facilitate selective binding, impacting phosphorylation events and modulating cellular signaling cascades. The reaction kinetics suggest a non-competitive inhibition pattern, influencing overall cellular proliferation. | ||||||
Cdk/Crk Inhibitor | 784211-09-2 | sc-203872 | 1 mg | $290.00 | ||
Cdk/Crk Inhibitor operates through a unique binding affinity for Cdk3, engaging in intricate hydrogen bonding and hydrophobic interactions that stabilize its complex with the enzyme. This interaction disrupts the ATP-binding site, effectively hindering substrate phosphorylation. The inhibitor's distinct molecular architecture promotes a conformational shift in Cdk3, altering its catalytic efficiency and impacting downstream signaling pathways. Its kinetic profile indicates a reversible inhibition mechanism, allowing for dynamic regulation of cellular processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Another CDK inhibitor that targets CDK3 along with other CDKs. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
A potent CDK inhibitor with selectivity for CDK1, CDK2, CDK5, and CDK9, but also exhibits some activity against CDK3. | ||||||
RGB-286638 | 784210-88-4 | sc-507523 | 250 mg | $285.00 | ||
A small molecule inhibitor of CDK3 with potential anticancer activity in cells. | ||||||
Aurora Kinase/Cdk Inhibitor | 443797-96-4 | sc-203829 | 5 mg | $440.00 | ||
A small molecule inhibitor that targets multiple CDKs, including CDK3. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Although primarily a CDK4/6 inhibitor, PD 0332991 also exhibits some inhibitory activity against CDK3. | ||||||